Page last updated: 2024-12-05

fidexaban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Fidexaban is a direct factor Xa inhibitor that is currently being investigated for its potential therapeutic benefits in a variety of cardiovascular conditions, including stroke prevention in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Its synthesis involves a multi-step process, beginning with commercially available starting materials. Fidexaban exhibits high affinity and selectivity for factor Xa, leading to inhibition of the coagulation cascade and reduction of thrombin generation. This mechanism of action makes fidexaban a promising candidate for the prevention and treatment of thromboembolic disorders. Research into fidexaban aims to assess its efficacy, safety, and optimal dosage regimen in various patient populations. Moreover, studies are being conducted to evaluate its potential benefits compared to existing anticoagulants, such as warfarin and rivaroxaban. Fidexaban's unique pharmacodynamic properties and its oral bioavailability make it a potentially valuable therapeutic option for the management of thromboembolic conditions. Further research is ongoing to fully elucidate its clinical utility and establish its place in current therapeutic strategies.'

Fidexaban: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4322
CHEMBL ID73193
SCHEMBL ID4354301
MeSH IDM0295473

Synonyms (34)

Synonym
zk 807834
ci-1031
zk-807191
bx-807834
zk-807834
fidexaban
pd-200022
D04183
fidexaban (usan/inn)
183305-24-0
n-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1h-imidazol-2-yl)phenoxy]pyridin-4-yl]-n-methylglycine
1FJS
chembl73193 ,
bdbm17284
2-{[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy]pyridin-4-yl](methyl)amino}acetic acid
SCHEMBL4354301
glycine, n-(2-(5-(aminoiminomethyl)-2-hydroxyphenoxy)-6-(3-(4,5-dihydro-1-methyl-1h-imidazol-2-yl)phenoxy)-3,5-difluoro-4-pyridinyl)-n-methyl-
((2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-(3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy)pyridin-4-yl)methylamino)acetic acid
n-(2-(5-(amino(imino)methyl)-2-hydroxyphenoxy)-3,5-difluoro-6-(3-(4,5-dihydro-1-methyl-1h-imidazol-2-yl)phenoxy)pyridin-4-yl)-n-methylglycine
10nhf3008v ,
unii-10nhf3008v
fidexaban [usan:inn]
fidexaban [inn]
[[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy]pyridin-4-yl]methylamino]acetic acid
zk807834
fidexaban [usan]
n-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1h-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-n-methylglycine
n-{2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy]pyridin-4-yl}-n-methylglycine
Q27251148
ci1031
bx807834
2-[[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid
n-(2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-(3-(1-methyl-4,5-dihydro-1h-imidazol-2-yl)phenoxy)pyridin-4-yl)-n-methylglycine
AKOS040748351

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The present study describes the human in vitro anticoagulant and pharmacodynamic profile ZK-807834."( Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031).
Abendschein, D; Ewing, J; Hinchman, JW; Light, DR; Post, JM; Sullivan, ME, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" However, five of six animals given the lowest effective dosage of rTAP and four of six animals given DX-9065a bled from a surgical incision >5 min, but only two of six animals given ZK-807834 bled >5 min."( Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Abendschein, DR; Baum, PK; Eisenberg, PR; Light, DR; Martin, DJ; Post, J; Rumennik, G; Sullivan, ME; Vergona, R, 2000
)
0.31
" To determine whether this reflects differences in the extent of vascular injury, we compared the dose-response of ZK-807834 for inhibition of venous thrombosis induced with a cotton thread and copper wire device in the presence and absence of balloon catheter-induced injury to the vena cava in rabbits."( Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Abendschein, DR; Baum, PK; Light, DR; Morser, J, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Coagulation Factor XaHomo sapiens (human)Ki0.00010.00010.00010.0001AID977610
ProthrombinHomo sapiens (human)Ki2.00000.00000.78469.0000AID211036; AID211218
Coagulation factor XHomo sapiens (human)Ki0.04010.00000.47089.0000AID1797609; AID51657; AID51676; AID51844; AID52158; AID527394
Cationic trypsinBos taurus (cattle)Ki0.21000.00001.07539.0000AID1797609; AID215191; AID215209
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID21450plasma concentration was measured against the Nonhuman primates (cynomolgus monkey) using FXa inhibition assay after 3 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID215191Compound was tested for inhibitory activity against bovine trypsin1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
AID21446plasma concentration was measured against the Nonhuman primates (baboon) using FXa inhibition assay after 4 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21442Inhibitor plasma concentration was measured in dogs on 10 mg/kg oral dosing after 4 hr administration; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID211036Compound was tested for inhibitory activity against human thrombin1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
AID52158In vitro inhibition of human coagulation factor Xa (Xa) in a purified enzyme system.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.
AID21444plasma concentration was measured against the Nonhuman primates (baboon) using FXa inhibition assay after 2 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21445plasma concentration was measured against the Nonhuman primates (baboon) using FXa inhibition assay after 3 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21448plasma concentration was measured against the Nonhuman primates (cynomolgus monkey) using FXa inhibition assay after 1 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21449plasma concentration was measured against the Nonhuman primates (cynomolgus monkey) using FXa inhibition assay after 2 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21441Inhibitor plasma concentration was measured in dogs on 10 mg/kg oral dosing after 2 hr administration; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID51844Binding affinity against Coagulation factor X2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID21447plasma concentration was measured against the Nonhuman primates (baboon) using FXa inhibition assay after 6 h; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21440Inhibitor plasma concentration was measured in dogs on 10 mg/kg oral dosing after 1 hr administration; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID89393Prothrombin time concentration to give a 2-fold extension activity against pooled lyophilized human plasma.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID527394Inhibition of factor 10a2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID20794oral bioavailability in dogs and monkeys.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID21443plasma concentration was measured against the Nonhuman primates (baboon) using FXa inhibition assay after 1 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID51657Compound was tested for inhibitory activity against human Coagulation factor X1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
AID215209Inhibitory potency was measured against bovine trypsin.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID211218Inhibitory potency was measured against human thrombin1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID51676Inhibitory potency was measured against human coagulation factor X1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID21451plasma concentration was measured against the Nonhuman primates (cynomolgus monkey) using FXa inhibition assay after 4 hr; uM1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme fa
AID1811Experimentally measured binding affinity data derived from PDB2000Biochemistry, Oct-17, Volume: 39, Issue:41
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Biochemistry, Oct-17, Volume: 39, Issue:41
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
AID1797609Enzyme Inhibition Assay from Article 10.1021/bi001477q: \\Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.\\2000Biochemistry, Oct-17, Volume: 39, Issue:41
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (14.29)18.2507
2000's15 (71.43)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews5 (23.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]